Latest Europe News

Ava Risk Group reported a solid start to FY2026 with $9 million in Q1 sales orders and a $7.5 million backlog, underpinning its guidance for a profitable first half.

Clever Culture Systems reports a cashflow positive quarter, expanding its pharmaceutical customer base and launching a new contact plate analysis module that promises to drive recurring revenues.

Arovella Therapeutics reported solid progress in Q1 FY26, moving closer to initiating its first-in-human trial for ALA-101 while securing key patents and maintaining a strong cash position.

Kuniko Limited has executed a binding earn-in agreement for a major Australian gold-silver project and raised A$2.7 million to fund exploration, while progressing its Norwegian battery metals portfolio.

Novonix Limited has achieved its first mass production of industrial-grade synthetic graphite and secured significant funding, advancing its position in North America's battery materials supply chain.

CurveBeam AI reports a 33% rise in device purchase orders and secures a $6.5 million placement alongside a landmark China distribution partnership. The company advances FDA regulatory milestones and establishes a vendor financing facility to boost sales.

Bioxyne Limited has reported a record quarterly revenue of A$14.1 million for Q1 FY26, driven by strong demand in Europe and Australia, alongside a strategic dual listing on the Frankfurt Stock Exchange.

SomnoMed reports a strong start to FY26 with 13.5% revenue growth and confirms the Clayton Sleep Institute as the first US site for its pivotal Rest Assure clinical study, backed by FDA protocol agreement.

Little Green Pharma reported a robust September quarter with revenue exceeding $10 million, driven by growth across all product lines and strong European market performance. The company is poised to benefit from upcoming regulatory reforms and operational efficiencies.

Sprintex Limited has transitioned from development to commercial execution, securing major contracts in Europe, China, and India while raising A$1.5m to fund expansion.

Activeport Group Ltd reported steady Q1 FY26 results with key project deliveries and a successful capital raise, positioning the company for accelerated growth across Asia and beyond.

Tissue Repair Limited reports steady progress in its Phase 3 clinical trials for chronic wound treatment and advances regulatory filings for its TR Pro+® product, while gearing up for a major commercial rollout in early 2026.